title: Paclitaxel in self-micro emulsifying formulations: oral  bioavailability study in mice.
abstract: The anticancer drug paclitaxel is formulated for i.v. administration in a mixture of Cremophor EL and ethanol.Its oral bioavailability is very low due to the action of P-glycoproteinin the gut wall and CYP450 in gut wall and liver.However, proof-of-concept studies using the i.v. formulation diluted in drinking water have demonstrated the feasibility of the oral route as an alternative when given in combination with inhibitors of P-glycoprotein and CYP450. Because of the unacceptable pharmaceutical properties of the drinking solution, a better formulation for oral application is needed.We have evaluated the suitability of various self-micro emulsifying oily formulations (SMEOF's) of paclitaxel for oral application using wild-type and P-glycoprotein knockout mice and cyclosporin A (CsA) as P-glycoprotein and CYP450 inhibitor. The oral bioavailability of paclitaxel in all SMEOF's without concomitant CsA was low in wild-type mice, showing that this vehicle does not enhance intestinal uptake by itself.Paclitaxel (10 mg/kg) in SMEOF#3 given with CsA resulted in plasma levels that were comparable to the Cremophor ELethanol containing drinking solution plus CsA. Whereas the AUC increased linearly with the oral paclitaxel dose in P-glycoprotein knockout mice, it increased less than proportional in wild-type mice given with CsA. In both strains more unchanged paclitaxel was recovered in the feces at higher doses. This observation most likely reflects more profound precipitation of paclitaxel within the gastro-intestinal tract at higher doses. The resulting absolute reduction in absorption of paclitaxel from the gut was possibly concealed by partial saturation of first-pass metabolism when P-glycoprotein was absent. In conclusion, SMEOF's maybe a useful vehicle for oral delivery of paclitaxel in combination with CsA, although the physical stability within the gastro-intestinal tract remains a critical issue, especially when applied at higher dose levels.
authors.affiliation: Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands. roosoostendorp@hotmail.com
authors.forename: Roos L
authors.initials: RL
authors.lastname: Oostendorp
authors.forename: T
authors.initials: T
authors.lastname: Buckle
authors.forename: G
authors.initials: G
authors.lastname: Lambert
authors.forename: J S
authors.initials: JS
authors.lastname: Garrigue
authors.forename: J H
authors.initials: JH
authors.lastname: Beijnen
authors.forename: J H M
authors.initials: JH
authors.lastname: Schellens
authors.forename: O
authors.initials: O
authors.lastname: van Tellingen
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000172:deficiency / Q000378:metabolism; D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical; D004655:Emulsions / Q000737:chemistry*; D005243:Feces; D005260:Female; D051379:Mice; D018345:Mice, Knockout; D017239:Paclitaxel / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D013997:Time Factors
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D004655:Emulsions; D017239:Paclitaxel
references.citation: Eur J Pharm Sci. 2000 Dec;12(2):103-10
references.pmid: 11102737
references.citation: Transplant Proc. 1993 Apr;25(2):1875
references.pmid: 8470210
references.citation: Br J Cancer. 2001 Nov 16;85(10):1472-7
references.pmid: 11720431
references.citation: Clin Cancer Res. 1998 Oct;4(10):2293-7
references.pmid: 9796957
references.citation: Ann Pharmacother. 1994 May;28(5 Suppl):S11-4
references.pmid: 7915152
references.citation: J Chromatogr B Biomed Appl. 1995 Feb 17;664(2):383-91
references.pmid: 7780591
references.citation: Ann Oncol. 2003 Feb;14(2):197-204
references.pmid: 12562644
references.citation: Br J Cancer. 2006 Oct 9;95(7):794-800
references.pmid: 16969354
references.citation: Clin Pharmacol Ther. 1996 Mar;59(3):297-303
references.pmid: 8653992
references.citation: J Chromatogr B Biomed Appl. 1995 Dec 15;674(2):261-8
references.pmid: 8788155
references.citation: J Clin Oncol. 2000 Jun;18(12):2468-75
references.pmid: 10856107
references.citation: Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2031-5
references.pmid: 9050899
references.citation: Lancet. 1998 Jul 25;352(9124):285
references.pmid: 9690410
references.citation: Cancer Res. 1999 Apr 1;59(7):1454-7
references.pmid: 10197613
references.citation: Cancer Invest. 1995;13(4):381-404
references.pmid: 7627725
references.citation: Ann Oncol. 1994;5 Suppl 6:S7-16
references.pmid: 7865438
references.citation: Br J Cancer. 2006 Sep 18;95(6):729-34
references.pmid: 16926835
references.citation: J Clin Oncol. 1997 Jan;15(1):110-5
references.pmid: 8996131
references.citation: Br J Cancer. 1999 Sep;81(2):330-5
references.pmid: 10496361
references.citation: Cancer Res. 1996 May 1;56(9):2112-5
references.pmid: 8616858
references.citation: J Clin Oncol. 2002 Dec 1;20(23):4508-16
references.pmid: 12454106
references.citation: Cancer Chemother Pharmacol. 2002 Feb;49(2):119-25
references.pmid: 11862425
references.citation: Eur J Pharm Biopharm. 2000 Jul;50(1):179-88
references.pmid: 10840200
references.citation: Br J Cancer. 1997;76(9):1181-3
references.pmid: 9365166
references.citation: J Pharmacol Exp Ther. 1995 Nov;275(2):566-75
references.pmid: 7473140
references.citation: J Pharm Sci. 2003 Dec;92(12):2411-8
references.pmid: 14603486